Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 vs Deucravacitinib in Moderate-to-Severe Plaque Psoriasis
2024-512497-10-00Phase 3Completed
- Sponsor
- Takeda
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Zasocitinib with Deucravacitinib (Sotyktu) (2 arms). Primary endpoint: PASI-100 response at Week 16. Started Aug 2025; status: completed.
02
Drugs
zasocitinibdeucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2024-512497-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512497-10-00.